sthrn labs is launching soon. Browse the catalog, review our COAs, and inquire to order.
CJC-1295 / Ipamorelin
A research combination of CJC-1295 (a GHRH analogue) and Ipamorelin (a selective GHRP), studied together for their synergistic effects on growth hormone secretion in preclinical models. For research use only.
Compound information
What is CJC-1295 / Ipamorelin?
Stability information
Research highlights
Component mechanisms: The areas below describe the documented mechanisms of the individual components — CJC-1295 and Ipamorelin — studied separately, not the combination. No combination-specific research exists (see Sources & references below).
Complementary pathway design
Research on pairing a GHRH analog (CJC-1295) with a selective GH secretagogue (Ipamorelin).
Synergistic GH release
Studies exploring combined amplitude and pulse effects on growth hormone secretion.
GHRH receptor stimulation
Studies on the short-acting GHRH analog's activation of pituitary GHRH receptors to stimulate growth-hormone release.
Physiologic pulsatility
Exploration of pulse-preserving GH stimulation versus continuous elevation.
Sources & references
Research ongoing
CJC-1295 / Ipamorelin is a fixed-combination product. No published studies exist on this specific blend; peer-reviewed literature exists on Ipamorelin individually, but not on the combination.
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
